Study Evaluating Safety and Tolerability of Vabicaserin in Patients With Sudden Worsening of Schizophrenia

A Randomized, Double-Blind, Risperidone-Reference, Parallel-Group, Safety, and Tolerability Study of Vabicaserin (SCA-136) in Japanese Subjects With Acute Exacerbation of Schizophrenia

This study will evaluate the clinical safety and tolerability of vabicaserin in Japanese subjects that have a sudden worsening of their symptoms of schizophrenia. The study will also assess the efficacy of vabicaserin and compare it to risperidone.

Inclusion Criteria:

• Male and female subjects between >=20 and =<65 years of age
• Current diagnosis and DSM-IV-TR diagnosis of schizophrenia type (295.10, 295.30 and 295.90)
• Total PANSS score >=70 and =< 120

Exclusion Criteria:

• Subjects who are hospitalized against their will
• Current Axis I primary psychiatric diagnosis other than schizophrenia
• A score of 3 on CDSS question 8 which pertains to suicide